Working with HPAPIs brings unique challenges in safety, containment, and scalability; challenges that Indena can face, being a global leader in development and production of high-quality and complex APIs and HPAPIs derived from plants, synthesis, semi-synthesis, and precision fermentation.
Moreover, HPAPIs are at the heart of revolutionary targeted therapies which are designed to deliver powerful treatments with precision, in fields like oncology and rare diseases. For example, Antibody-Drug Conjugates (ADCs) are one of the fastest-growing segments in pharmaceutical innovation, combining the targeting capability of antibodies with potent therapeutic payloads. And Indena’s expertise includes payload-linkers – the key component of ADCs – with a backward integration on fermentation for toxins requiring this step and freeze-drying ability in high containment. To accelerate the development of innovative and market-ready payload-linkers Indena will collaborate with TCG GreenChem combining complementary capabilities.
.
To know more, come at ChemOutSourcing–Booth 31 to meet @Bernard Vianès and Indena’s team.
